Sign Out
Pregnancy: No clinical data on exposed pregnancies are available for Etoricoxib. The potential for human risk in pregnancy is unknown. Etoricoxib, as with other medicinal products inhibiting prostaglandin synthesis, may cause uterine inertia and premature closure of the ductus arteriosus during the last trimester. Etoricoxib is contraindicated in pregnancy. If a woman becomes pregnant during treatment, Etoricoxib must be discontinued.
Breastfeeding: It is not known whether Etoricoxib is excreted in human milk. Women who use Etoricoxib must not breastfeed.
Fertility: The use of Etoricoxib, as with any drug substance known to inhibit COX-2, is not recommended in women attempting to conceive.
